Nutritional supplements for older adults: Review and Recommendations-Part II

Journal of Nutrition for the Elderly

Volumn 29, Issue 1, 2010, Pages 42-71

  Buhr, Gwendolen ^a   Bales, Connie W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fish oils; Folate; Folic acid; Health outcomes; Older adults; Omega 3 fatty acids; Supplements; Vitamin B12; Vitamin B6

Indexed keywords

OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; VITAMIN B COMPLEX;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DEPRESSION; DIET SUPPLEMENTATION; HUMAN; NEOPLASM; RETINA MACULA DEGENERATION;

AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DEPRESSION; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MACULAR DEGENERATION; NEOPLASMS; TRIGLYCERIDES; VITAMIN B COMPLEX;

EID: 77951079444     PISSN: 01639366     EISSN: 15408566     Source Type: Journal    
DOI: 10.1080/01639360903586464     Document Type: Article

References (117)

1. Carmel R. Cobalamin, the stomach, and aging. Am J Clin Nutr. 1997; 66(4):750-9.
2. Martin DC, Francis J, Protetch J, Huff FJ. Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. J Am Geriatr Soc. 1992; 40(2):168-72.
3. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969; 56(1):111-28.
4. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338(15):1042-50.
5. 6: A randomised trial. Eur J Clin Nutr. 2003; 57(11):1426-36.
6. 12, Pantothenic Acid, Biotin, and Choline. Food and Nutrition Board. Washington, DC: National Academy Press; 1998.
7. van Asselt DZ, van den Broek WJ, Lamers CB, Corstens FH, Hoefnagels WH. Free and protein-bound cobalamin absorption in healthy middle-aged and older subjects. J Am Geriatr Soc. 1996; 44(8):949-53.
8. Scarlett JD, Read H, O'Dea K. Protein-bound cobalamin absorption declines in the elderly. Am J Hematol. 1992; 39(2):79-83.
9. 12 deficiency in elderly inpatients. Age Aging. 1989; 18:4-10.
10. Ho C, Kauwell GP, Bailey LB. Practitioners' guide to meeting the vitamin B-12 recommended dietary allowance for people aged 51 years and older. J Am Diet Assoc. 1999; 99(6):725-7.
11. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994; 120(3):211-5.
12. 12 status in older adults? J Am Med Dir Assoc. 2008; 9(3):162-7.
13. 12 deficiency in older adults. J Clin Epidemiol. 2004; 57(4):422-8.
14. Ribaya-Mercado JD, Russell RM, Sahyoun N, Morrow FD, Gershoff SN. Vitamin B-6 requirements of elderly men and women. J Nutr. 1991; 121(7):1062-74.
15. Clarke R, Grimley Evans J, Schneede J, et al. Vitamin B12 and folate deficiency in later life. Age Ageing 2004; 33(1):34-41.
16. Rampersaud GC, Kauwell GP, Bailey LB. Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr. 2003; 22(1):1-8.
17. Food and Drug Administration. Final Rule. Food Standards: amendment of Standards of Identity for Enriched Grain Products to Require Addition of Folic Acid. Federal Register 1996; 61:8781-8797.
18. Health Canada. Regulations amending the food and drug regulations: schedule No. 1066 (flour fortification). Canada Gazette Part II 1998; 132(24).
19. Garcia AA, Day AG, Zanibbi K, Zunzunegui MV. Long-term effects of folic acid fortification and B-vitamin supplementation on total folate, homocysteine, methylmalonic acid and cobalamin in older adults. Can J Public Health 2008; 99(5):428-33.
20. Mulligan JE, Greene GW, Caldwell M. Sources of folate and serum folate levels in older adults. J Am Diet Assoc. 2007; 107(3):495-9.
21. Choumenkovitch SF, Selhub J, Wilson PW, Rader JI, Rosenberg IH, Jacques PF. Folic acid intake from fortification in United States exceeds predictions. J Nutr. 2002; 132(9):2792-8.
22. Wakimoto P, Block G. Dietary intake, dietary patterns, and changes with age: an epidemiological perspective. J Gerontol A Biol Sci Med Sci. 2001; 56(90002):65-80.
23. Marshall TA, Stumbo PJ, Warren JJ, Xie XJ. Inadequate nutrient intakes are common and are associated with low diet variety in rural, community-dwelling elderly. J. Nutr. 2001; 131(8):2192-2196.
24. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology. 2002; 58(10):1471-1475.
25. 6 status after ischemic stroke. Stroke. 2004; 35(1):12-15.
26. Chiang EP, Bagley PJ, Selhub J, Nadeau M, Roubenoff R. Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med. 2003; 114(4):283-7.
27. Essama-Tjani JC, Guilland JC, Potier de Courcy G, Fuchs F, Richard D. Folate status worsens in recently institutionalized elderly people without evidence of functional deterioration. J Am Coll Nutr. 2000; 19:392-404.
28. Rydlewicz A, Simpson JA, Taylor RJ, Bond CM, Golden MHN. The effect of folic acid supplementation on plasma homocysteine in an elderly population. QJM. 2002; 95(1):27-35.
29. Murú AL, Quintana I, Janson J, Batista M, Camera MI, Kordich LC. Plasmatic homocysteine response to vitamin supplementation in elderly people. Thrombosis Research 2000; 100(6):495-500.
30. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296(22):2720-6.
31. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288(16):2015-22.
32. Van Guelpen B, Hultdin J, Johansson I, et al. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med. 2009; 266:182-195.
33. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation. 2002; 105(1):22-6.
34. de Bree A, van Mierlo LA, Draijer R. Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2007; 86(3):610-7.
35. Lonn E. Homocysteine-lowering B vitamin therapy in cardiovascular prevention-wrong again? JAMA. 2008; 299(17):2086-7.
36. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004; 291(5):565-75.
37. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354(15):1578-88.
38. The Heart Outcomes Prevention Evaluation Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354(15):1567-1577.
39. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008; 299(17):2027-36.
40. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008; 300(7):795-804.
41. Martí-Carvajal A, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2009; (4).
42. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009; 40(4):1365-72.
43. Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc Disord. 2008; 8:24.
44. Stroke Trials Registry. VITATOPS 2009; [updated 3 November 2009]. Accessed at http://www.strokecenter.org/trials/TrialDetail.aspx?tid=87 on 9 December 2009.
45. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007; 369(9576):1876-82.
46. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006; 47(6):1108-16.
47. Vianna ACA, Mocelin AJ, Matsuo T, et al. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodialysis International. 2007; 11(2):210-216.
48. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007; 298(10): 1163-1170.
49. Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007; 154(5):815-23, 823 e1-6.
50. 12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003; 7(6):428-35.
51. Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S. The SU FOL OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/ or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials. 2008; 9:35.
52. Raman G, Tatsioni A, Chung M, et al. Heterogeneity and lack of good quality studies limit association between folate, vitamins B-6 and B-12, and cognitive function. J Nutr. 2007; 137(7):1789-94.
53. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006; 580(13):2994-3005. Epub 2006 May 6.
54. Ho PI, Collins SC, Dhitavat S, et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem. 2001; 78(2):249-53.
55. Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol. 2007; 64(1):86-92.
56. 12 for cognition. Cochrane Database Syst Rev. 2003(3):CD004326.
57. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000; 71(2):614S-620S.
58. Calvaresi E, Bryan J. B vitamins, cognition, and aging: a review. J Gerontol B Psychol Sci Soc Sci. 2001; 56(6):P327-39.
59. 12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev. 2008(4):CD004514.
60. 12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med. 2007; 167(1):21-30.
61. 6 on cognition. Cochrane Database Syst Rev. 2003(4):CD004393.
62. Brady CB, Gaziano JM, Cxypoliski RA, et al. Homocysteine lowering and cognition in CKD: the Veterans Affairs Homocysteine Study. Am J Kidney Dis. 2009; 54(3):440-9.
63. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008; 300(15):1774-1783.
64. 12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther. 2007; 29(10):2204-14.
65. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L. Homocysteine and depression in later life. Arch Gen Psychiatry. 2008; 65(11):1286-94.
66. Folstein M, Liu T, Peter I, et al. The homocysteine hypothesis of depression. Am J Psychiatry. 2007; 164(6):861-7.
67. Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health. 2007; 61(7):631-7.
68. 6 is associated with depressive symptomatology in Massachusetts elders. J Am Coll Nutr. 2008; 27(3):421-7.
69. Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990; 336(8712):392-5.
70. Hvas AM, Juul S, Lauritzen L, Nexo E, Ellegaard J. No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study. J Affect Disord. 2004; 81(3):269-73.
71. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000; 60(2):121-30.
72. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol. 2004; 18(2):251-6.
73. 6, and folic acid for onset of depressive symptoms in older men: results from a 2-year placebo-controlled randomized trial. J Clin Psychiatry. 2008; 69(8):1203-9.
74. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer. 2005; 113(5):825-8.
75. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007; 297(21):2351-2359.
76. Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008; 134(1):29-38.
77. Wu K, Platz EA, Willett WC, et al. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr. 2009; 90(6):1623-31.
78. Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009; 101(6):432-5.
79. 12 on cancer risk in women: a randomized trial. JAMA. 2008; 300(17):2012-21.
80. 12. JAMA. 2009; 302(19):2119-26.
81. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007; 16(7):1325-9.
82. Heuberger RA, Fisher AI, Jacques PF, et al. Relation of blood homocysteine and its nutritional determinants to age-related maculopathy in the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2002; 76(4):897-902.
83. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009; 169(4):335-41.
84. 12 insufficiency among elderly women after folic acid food fortification. Clin Biochem. 2003; 36(5):387-91.
85. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr. 2007; 85(1):193-200.
86. Bang H, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper H (Ed), Advances in Nutrition Research. New York: Planum Press; 1980.
87. Connor WE. Importance of n-3 fatty acids in health and disease1. Am J Clin Nutr. 2000; 71(1):171S-175.
88. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (Macronutrients). Washington, DC: National Academy Press; 2005.
89. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114(1):82-96.
90. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006; 296(15):1885-1899.
91. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999; 354(9177):447-55.
92. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002; 105(16):1897-903.
93. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006; 189(1):19-30.
94. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care. 1998; 21(4):494-500.
95. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002; 20(8):1493-9.
96. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. Atherosclerosis. 2006; 184(2):237-46.
97. Angerer P, Kothny W, Stork S, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res. 2002; 54(1):183-90.
98. Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007; 191(1):162-7.
99. De Ley M, de Vos R, Hommes D, Stokkers P. Fish oil for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews; 2007.
100. Turner D, Steinhart A, Griffiths A. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007: CD006443.
101. Turner D, Zlotkin S, Shah P, Griffiths A. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2009: CD006320.
102. Thien F, De Luca S, Woods R, Abramson M. Dietary marine fatty acids (fish oil) for asthma in adults and children. Cochrane Database of Systematic Reviews 2002: CD001283.
103. Appleton KM, Peters TJ, Hayward RC, et al. Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association? Soc Psychiatry Psychiatr Epidemiol. 2007; 42(2):100-4.
104. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr. 2008; 99(2):421-31.
105. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006; 63(11):1545-50.
106. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007; 85(4):1142-7.
107. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 2007; 85(4):1103-11.
108. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. 2008; 71(6):430-8.
109. Dangour AD. The opal study: older people and n-3 long-chain polyunsaturated fatty acids. International Standard Randomised Controlled Trial Number Register 2004; [cited 22 March 2009]. Accessed at http://www.controlled-trials.com/ISRCTN72331636.
110. Terano T, Fujishiro S, Ban T, et al. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids 1999; 34 Suppl:S345-6.
111. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006; 63(10):1402-8.
112. Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? Arch Pathol Lab Med. 2003; 127(12):1603-5.
113. U.S. Department of Health and Human Services and U.S. Environmental Protection Agency. What You Need to Know About Mercury in Fish and Shellfish. 2004; [cited 22 March 2009]. Accessed at http://www.cfsan.fda.gov/dms/admehg3.html
114. Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006; 84(1):5-17.
115. Dietrich M, Brown CJP, Block G. The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr. 2005; 24(4):266-274.
116. Lewis CJ, Crane NT, Wilson DB, Yetley EA. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am J Clin Nutr. 1999; 70(2):198-207.
117. Department of Health and Human Services, Food and Drug Administration. Substances affirmed as Generally Recognized As Safe: Menhaden oil. Federal Register 1997; 62:30751-30757.